Jornet holds the fastest known time speed record for the ascent and descent of major mountains including Mont Blanc and ...
Results from the MATTERHORN Phase III trial showed perioperative treatment with AstraZeneca’s (AZN) Imfinzi in combination with ...
11h
Edinburgh News on MSNEdinburgh residents are seeking relaxation in their travel in 2025, new study revealsA fifth (20%) of those from Edinburgh say they’re seeking a place to provide relaxation from their 2025 travel.
1d
ExplorersWeb on MSNOne of the Last Wild Faces in the Alps Finally ClimbedPunta Pioda doesn't have the same notoriety as the north faces of the Eiger, the Matterhorn, or the Grandes Jorasses. But ...
Positive high-level results from the MATTERHORN Phase III trial showed perioperative treatment with AstraZeneca’s (AZN) Imfinzi in combination ...
9h
Belfast News Letter on MSNA quarter of people from Belfast are seeking adventure from their 2025 travelA quarter (25%) of those from Belfast say they’re seeking a place for adventure from their 2025 travel. This is according to ...
Preliminary trial results demonstrated that Imfinzi plus chemo improved event-free survival in resectable early-stage gastric ...
MATTERHORN is the first global phase 3 trial to show improved event-free survival with an immunotherapy combo vs standard ...
AstraZeneca is preparing to talk to the FDA about a potential new use of its immunotherapy Imfinzi after a pivotal study in ...
3d
GlobalData on MSNAstraZeneca reports positive outcomes from trial of ImfinziAstraZeneca has reported positive “high-level” outcomes from the randomised Phase III MATTERHORN trial of Imfinzi (durvalumab ...
Imfinzi is one of AstraZeneca’s key growth drivers for 2025, with potential approvals in stomach and bladder cancers. The ...
AstraZeneca Plc (NASDAQ:AZN) released high-level results from the MATTERHORN Phase 3 trial evaluating Imfinzi (durvalumab) as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results